Delhi High Court admitted Novartis India's writ petition on March 27, 2026, challenging a DVAT assessment for AY 2013–14.
The disputed demand totals approximately ₹10.89 crore in tax and interest plus a penalty of ₹6.85 crore raised by the Commissioner of Trade and Taxes.
A favorable order could yield a refund of ₹54.45 lacs; an unfavorable outcome carries no financial impact as the pre-deposit is fully provided for in the books.